Celosia Therapeutics is a clinical‑stage biotechnology company developing disease‑modifying therapies for neurodegenerative disorders with high unmet need.

Why work with us

Celosia Therapeutics is advancing a first-in-class gene therapy for ALS, specifically targeting TDP-43 pathology.

Our lead program, CTx1000, targets pathological TDP‑43 protein aggregates in ALS and frontotemporal dementia. CTx1000 is currently being evaluated in a Phase 1b clinical trial.

Celosia is preparing for a Series B financing in 2026 and is actively seeking a lead investor and strategic partners to support the next phase of clinical development and expansion.